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TnE neutral 17-ketosteroids excreted in the urine ofnormal women are mainlv
metabolites of the hormones of the adrenal cortex. They can be separated bv
chromatography into two main fractions, those which have an oxygen atom at the
I I-position in the steroid nucleus (the II-oxy 17-ketosteroids) and those in which
this fimetion is not present (the 11-deoxy 17-ketosteroids). The 11-oxygenated
steroids are mainly derived from the 21 carbon atom (C21) glueocorticoids, i.e.,
cortisol while the 11-deoxy compounds are for the most part excretion products
of the C19 androgenic hormones. In this paper we report the results of esti-
mating these urinarv steroids in women with advanced breast cancer treated bv
endocrine surgery.
METHODS
Urinarv 17-ketosteroids and their fractions were estimated in women '"ith
metastatic or recurrent mammarv cancer treated bvoophorectomy, adrenalectomv
or radioactive implantation of the pituitarv gland (Forrest, el al., 1959). Collec-
tions of urine for assav were made while the patients were in hospital, the urine
being collected in clean bottles and stored below 4' C.
Total neutral 17-ketosteroids were estimated in duplicate on 100 ml. aliquots of
t-otal 24-hour urine collections bv the method advised by the Chnical Endocrino-
logical Committee of the Medical Research Council (1951). After acid hydrolysis
the fi-ee steroids were extracted with carbon tetrachloride and phenolic steroids
(oestrogens) removed bv an alkahne wash. The concentration of rema'
i
neutral 17-ketosteroids was estimated colorimetricauv by the Canow-Zimmerman
reaction.
17-Ketoskraid fractions.-Fractionation of 17-ketosteroids was carried out
on 24-hour or pooled 72-hour coRections of urine by the method described in
det,ail elsewhere (Hobkirk, 1958). -After initial saturation of the urine with
ammonium sulphate ((NH4)2 SO,) the glucuronide and sulphate steroid conju-
gates were extracted bvshakingwith ether-ethanol (3: 1) andsucces-sivelyhydroly-
sed bv hmpet d-glucuronidase and hvdrochloric acid at room temperature. The
resulting fi-ee steroids were extracted with ether, washed with alkali and ketonic
fractions prepared with Girard T reagent. These were separated into 3a and 3,8
hvdroxysteroids bv treatment with digitonin. Further fmctionation of the 32
hvdroxysteroids into IIfl-hydroxyaetiocholanolone plus I1.6-hydroxyandosterone, 11-ketoaetiochololonel, 11-ketoandrosteronel androsterone and aetiocholanolone
was carried out bvchromatography on paper in a hgroin-propylene glycol system.URINARY 17-KETOSTEROIDS IN BREAST CANCER
Quantitative estimations of each fraction was carried out by a modification of
the Callow-Zimmerman reaction (Wilson, 1954), absolute values for each steroid
being obtained by reference to calibration curves for the pure compounds. Where
amounts permitted, ultraviolet absorption curves ofthe chromatographic fractions
in concentrated sulphuric acid yielded further proof of identity. The probable
source of these fractions are shown in Table I.
TABLE I.-Neutral 17-ketosteroid Fractions in Female Urine
and their Probable Source
3 Hydroxyl
Hormone Urinary metabolite Ketosteroid fraction orientation
Cortisol 1 fl-Hydroxyandrosterone
1lfl-Hydroxyaetiocholanolone
1lfl-Hydroxy A4-Androstendione 1 .-Ktadroster one 11-oxy 17-ketosteroids 3a fraction H#l-Hydroxy, A4-Androstendione I1l-Ketoandrosterone
Cortisone 1 -Ketoaetiocholanolone
A4Anrsee31dAndrosterone
11-deox 17-ketosteroids a4-Andlrostene 3, 17-dilone Aetiocholanolone 1 d
Dehydroepiandrosterone Dehydroepiandrosterone 3fl fraction
RESULTS
Total neutral 17-ketosteroids
Adrenalectomy and oophorectomy.-In twelve post-menopausal women with
breast cancer total neutral 17-ketosteroids were estimated in at least three 24-
hour collections ofurine before and in at least three collections made 1 to 3 months
after adrenalectomy and oophorectomy. Post-operative urine was collected while
patients were receiving maintenance cortisone (50 mg./day) and also during a
5-day period when they were given 120 units corticotrophin (ACTH) gel daily by
intramuscular injection. Six of the twelve patients had objective evidence of
regression ofcancer following the operation; in the others the course ofthe disease
was not affected.
The excretion ofneutral 17-ketosteroids in the urine was significantly depressed
by surgical removal of the adrenals and ovaries (Table 11-mean difference ±
standard error: 1P4 ± 0-6 mg./24 hr; P < 0.05). The mean fall in the six
patients whose cancer regressed was identical to that in those who did not benefit.
In neither group of patients did ACTH produce a significant increase in keto-
steroid excretion (Table II-mean difference in responding patients-0-4 + 0-6
mg./day; in non-responding patients + 0-2 ± 0 5 mg./day. Fig. 1).
TABLE II.-Mean Excretion of Total Neutral 17-ketosteroids (mg. per day) in
12 Patients with Breast Cancer Before andafterAdrenalectomy and Oophorectomy
Cancer Cancer not
regressed improved
(6 patients) (6 patients) Total
Before adrenalectomy-no cortisone . . . . 4-5 . 4-3 . 4-4
After adrenalectomy-cortisone 50 mg. per day 3-1 . 2-9 3 0
After adrenalectomy-cortisone 50 mg. ACTH 120 units . 2-7 . 3- 1 2-9
Pituitary implantation.-Serial daily estimations of total neutral 17-keto-
steroids were made in eighteen post-menopausal women with breast cancer before
33
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and after iniplantation of the pituitary with Yttrium-90. Urine was collected
post-operatively while patients were receiving maintenance cortisone 50 mg./dav.
The pre-operative results are the means of three to six determinations while
the post-operative means are those ofall estimations carried out within 3 months of
implantation. Nine patients had regression of cancer as a result of pituitary
destruction. Neither in them nor in the other nine patients whose cancer faile(I
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Fie.. I.-Effect of ACTH (1-90 units per day for 5 days) on urinary neutral 17-ketosteroids followitig
adrenalectomy and oophorectoiny in twelve patients with advanced breast cancer.
to respond, did pituitary implantation lead to significant reduction of total
1-1-ketosteroid excretion (Table III Fig. 2).
TA13LE III.-Mean Excretion of Total Neutral 17-keto,3teroids (mg. per day) in
18 Patient-s Before and After Implantation of the Pituitary with Yttrium-90
Cancer
regi-essed
(9 patients)
3 5
3 -2
-0-3 -'0-4
() 4
Cancer not
improved
(9 patients)
3- 6
3 9
0-3±0- 9
->O. 7
Total
3 5
3 -.5
1-3efore implant-no cortisone
After implant-cortisone 50 iiig. per day
Mean difference
p
.Veutral 17-k-eto8teroidflraction-s
Pre-operative e8timations.-Neutral 1-i-ketosteroid fractions were estimated
on 3-day pools ofurine in twentv-two patients with advanced breast cancer before
treatment bv endocrine surgery. Five of the patients had functioning ovaries
at the time of estimation (marked with P. Fig. 3). In two patients only the total
I IAeoxy and I I-oxy fractions were estimated
- in the other twenty patients fullfractionation was carried out. The excretion ofthese fractions in twelve patients
who had subsequent regression of cancer was quantitatively similar to that in
tenpatients who had no response to treatment (Table IV ; Fig. 3). The means of
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FiG. 3.-Urinary 17-ketosteroid fractions in twenty-two women with advanced breast cancer
before endocrine surgery has been performed.
the two groups ofpatients were compared by Students
" t
" test using both the
arithmetic values and the ( x IO)logarithms oftheoutputs ofketosteroid fractions.
No significant difference was revealed (Table V). The ratio of I I-deoxy to I1-oxy 17-ketosteroids was also unrelated to the response to endocrine surgery (TableVI).
I
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FIG. 2.-Neutral 17-ketosteroids in the urine of eighteen patients with advanced breast cancer
before and after implantation of the pituitary with Yttrium-90.
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TABLE IV.-Mean Excretion of Urinary 17-ketosteroid Fractions in 20 Women
with Brea,3t Cancer Before Endocrine Surgery. Two Patients in Whom Only
Total 11-oxy and 11-deoxy 17-keto8teroid8 were Kstimated are Not Included in
this Table but Are Included in Table-s V and VI and Fig. 3
11-oxy 17-ketosteroids 11-deoxy 17-ketosteroids
r
Response to I I-OH F,
endocrine surgerv I I-OH A I I-KE I I-KA Total E A fraction Total
Cancer regressed 0- 52 0- 31 0.10 0- 93 0- 93 0- 71 0-12 1- 76
(II patients)
Cancer not improved 0- 74 0- 44 0- 08 1- 26 1- 32 0 87 0- 03 2- 22
(9 patients)
11-OH E Ilfl-Hydroxyaetiocholanolon.e.
I I -OH A IIfl-Hydroxyandrosterone.
11-KE I I-Ketoaetiocholanolone.
11-KA I I-Ketoandrosterone.
E Aetiocholanolone.
A Androsterone.
TABLE V.-CoMparison of the Mean Pre-operative Excretion of 17-ketosteroid
Fractions in Twelve Patients Whose Cancer Sub,8equently Improved Following
Endocrine Surgery and in 10 Patients in Whom There Was No Response
11-oxy 17-ketosteroids II-deoxy 17-ketosteroids
Response to Number of A ---"% t -14-
'%
endocrine surgery patients Arithmetic Logarithmic Arithmetic Logarithniie
Cancer regressed 12 0- 94 0- 864 1- 83 1 073
Cancer not improved 10 1- 23 1- 038 2- 28 1- 236
Mean difference -L- S.E. 0-29± 0- 258 0- 1744-0- 130 0-45+0- 617 0-1634-0-198
p >0.2 >0. I >0.4 >0-4
Po-st-operative estimation8.-Estimations of neutral 17-ketosteroid fractions
on 24-hour orpooled 3-day collections of urine were made in sixteen patients after
adrenalectomy and oophorectomy and on pooled 3-day collections in twenty-
two patients after Yttrium-90 implantation of the pituitary. In both groups of
patients urine was collected within 12 months of surgery while cortisone therapy
(50 mg./day) was being taken. Significant amounts of 11-oxy 17-ketosteroids
were present in the urine of all patients, being the excretion products of mainten-
ance cortisone (Fig. 4 and 5). The amounts of these fractions were not related to
the clinical response (Tables VII and VIII). The means in the groups ofpatients
were statistically compared as above ; no significant difference was demonstrated
(Table IX).
Adrenalectomy and oophorectomy led to the complete disappearance of I I
deoxy 17-ketosteroids in four of ten patients whose cancer responded to the opera-
tion and in five of six patients whose cancer did not improve. In six patients
in the responding group trace amounts of aetiocholanolone only were detected
while in one patient who failed to benefit, small but significant amounts of aetio-
cholanolone and androsterone were present (Table X).
Implantation of the pituitary with Yttrium-90 was less effective in reducing the excretion of I I-deoxy 17-ketosteroids although in five oftwelve patients whose
cancer regressed and in four of ten patients who had no response, no measurable
amounts of these fractions were present in the urine. In the other patients in
both groups variable amounts of one or more fractions were detected (Table XI).URINARY 17-KETOSTEROIDS IN BREAST CANCER 465
The mean outputs of 11-deoxy 17-ketosteroids were statistically compared in
patients who responded and in those who failed to improve foHowing pituitary
implantation with Yttrium-90. Nosignificant difference waspresent (Table XII).
II Deoxy
17-Ketos
mg per
24 hrs
It-Oxy
17-Ketos
FiG. 4.-Urinary 17-ketosteroid fractions in sixteen women with advanced breast cancer
treated by adrenalectomy and oophorectomy.
I I
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FIG. 5.-Urinary 17-ketosteroid fractions in twenty-two patients with advanced breast cancer
treated by implantation of the pituitary with Yttrium-90.
DISCUSSION
The estimation of total neutral 17-ketosteroids in female urine is a crude and
relatively non-specific index of adrenocortical activity. In patients with breast
cancer their excretion was consistently reduced by adrenalectomy and oophorec- tomy, irrespective of the chnical response of the patient, a finding previously11-deoxy 17-ketosteroids
A
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TABLEVI.-Pre-operative Estimations of Urinary 17-keto8teroid Fractions in
Patients with Breast Cancer Treated by Endocrine Ablation.
17-ketosteroid fraction
(mg./day)
A
I-deoxy II-oxy
17KS 17 KS Ratio: I
0 0- 26 .. I
0- 34 0- 49 0- 7
1- 20 1- 33 0.9
1- 39 1.15 1- 2
0- 27 0-19 1- 4
3- 10 2- 06 1.5
2- 33 1- 45 1.6
2-47 0- 97 2- 5
2
- 63 1- 03 2- 6
1- 24 0- 48 2- 6
5- 48 1- 62 3- 4
1.55 0- 27 5- 7
Behaviour
of cancer
Cancer regressed
(12 patients)
Case
number
Ox 22
8 20
Ys 16
Ys 10
8 39
Ys 13
Ys 14
S 44
As 6
Ys 27
Ox I
As 38
Mean
ratio
1
2- :1
Endocrine Surgery
Oophorectomy
Pituitary implant
Oophorectomy
+Pituitary implant
Pituitary implant
Adrenalectomy
+ Oophorectomy
Pituitary implant
Oophorectomy
Adrenalectomy
+ Pituitary implant
Pituitary implant
Oophorectomy
+ Pituitary implant
Pituitary iniplant
Oophorectomy
. Adrenalectomy
. Pituitary implant
Pituitary implant
Oophorectomy
+ Pituitary implant
Pituitary implant
Adrenalectomy
+ Pituitary implant
Pituitary implant
Adrenalectomy
.+ Pituitary implant
Cancer not improved
(10 patients)
Ys 25
s I
Ys 9
As 41
0- 26
2- 36
I
- 38
0- 44
1-43
3- 39
3- 07
2- 85
4.29
3- 35
1- 59
2- 56
1.00
0- 32
0- 94
1- 56
1- 29
0- 98
1- 22
0- 82
0-2
'
0- 9
1- 4
1- 4
1-5
2- 2
2- 4
2- 9
3- 5
4- 1
. 2-1: 1 Ys 12
Yis 11
Ys 18
As 5
Ys 15
Ys 10
TABLE VII.-Mean Excretion of Urinary 17-ketO8teroid Fraction8 After
Adrenalectomy and Oophorectomy in 16 Women with Brea8t Cancer
11-oxy 17-ketosteroids 11-deoxy 17-ketosteroids
.sponse to r A -"% t -A- I
endocrine 110H E
surgery 110HA 11 KE 11
Cancer regressed (10 0-58 0-92 0.
patients)
Cancer notimproved 0-49 0-46 0
(6 patients)
Re
KA Total
- 02 1-52
0.95
E
0.01
A Total
0 0 0.01
0- 04 0- 04 0 0-08
TABLEVIII.-Mean Urinary Excretion of 17-ketO8teroid Fractions After
Pituitary Implantation with Yttrium-90 in 22 Women with Breast Cancer
11-oxy 17-ketosteroids
Response to r
endocrine IIOH F,
surgery IIOHA IIKE IIKA Total
Cancer regressed 0- 73 0-59 0- 06 1-38
(12 patients)
Cancer not iinproved 0-53 0- 39 0.04 0- 96
(10 patients)
E A p Total
0-18 0.05 0.06 0-29
0-23 0.10 0-02 0-35URINARY 17-KETOSTEROIDS IN BREAST CANCER 467
T-ABLE IX.-Comparison of Mean Postoperative Excretion of II-oxy 17-ketosteroids
in I0 Patients Who Responded and 6 Patients Who Did Not Respond to
Adrenalectomy and in 12 Patients Who Re8ponded and 10 Patients Who did
Not Re8pond to Pituitary Implantation
Mean 11-oxy-
Number 17-ketosteroid excretion
of r I patients Arith. Log.
10 1.51 1- 063
6 0-93 0- 770
0-58±0- 540 0-293±0-212
>0-3 >0. I
Nature of
endocrine surgery
Oophorectomy and Adrenal.
ectomy
Response to
endocrine surgery
Cancer regressed
Cancer not improved
Mean difference
p
Pituitary implaritation Cancer regressed
Cancer not improved
Mean difference
p
12
10
1- 38
0.96
0-419±0-509
>0-4
0- 916
0- 839
0-077±0-191
>0.6
TABLEX.-The Excretion of Urinary II-deoxy 17-ketO8teroid8 After Adrenalectomy
in 7 Women With Brea8t Cancer. In the, Other 9 Patient8 Studied After
Adrenalectomy and Oophorectomy No II-deoxy I7-ket08teroid8 Were Pre8ent
Response to
endocrine
surgery
Cancer regressed
-
Cancer not improved
11-deoxy 17-ketosteroids
A
.1 r
E A
0-03 0 0
0- 01 0 0
0-04 0 0
0- 01 0 0
0.01 0 0
0- 02 0 0
0-16 0.15 0
Patient
As 17
As 9
As 7
As 38
As 26
Ax 4
As 5
TABLE XI.-The Excretion of Individual II-deoxy 17-ketosteroids After Pituitary Implantation With 90Y in 13 Women With Breast Cancer
Response to
endocrine
surgery
Cancer regressed
11-deoxy 17-ketosteroids
A
I' ----I
E A
0- 20 0 0.10
0- 83 0.19 1-20
0- 26 0 0
0- 45 0- 35 0-14
0- 07 0- 02 0- 27
0.09 0 0
0-04 0 0.01
Patient
Ys 14
8
Yu
Ys
Ys
Ys
Ys
3
10
6
3
1
22
Cancer not improved Ys
Ys
Ys
s
s
Ys
15
10
25
37
66
23
0- 16
1- 72
0-28
0- 02
0- 12
0
0.11
0- 68
0
0- 04
0.19
0
0
0
0.01
0
0- 17
0.01468 SIM, HOBKIRK STEWART BLAIR AND FORREST
TABLE XII.-Comparison of Mean Excretion of I1-deoxy 17-ketosteroids in 12
Patients Who Responded and I0 Patients Who did Not Re8pond to Pituitary
Implantation
Respori.se to Nuinbet- Alean 11-deoxy-17-ketostei-oids
endocrine of
surgery patients Arith. Log.
Cancer regressed 12 0- 27 0- 292
Cancer not iinproved I0 0 35 0- 295
Mean differenee 0-084+0-250 0-003±0-184
p >0.8 >0.9
reported by Strong et al. (1956). ln the adrenalectomized patient the smaR
amounts of total 17-ketosteroids excreted in the urine are metabolites of mainten-
ance cortisone, and if this is temporarily stopped they fall to undetectable levels
(Hobkirk et al., 1959).
In women with breast cancer whose adrenals have not been removed ACTH
administration leads to increased excretion ofurinary total 17-ketosteroids. This
effect was not noted in any of the adrenalectomized patients studied, indicating
that these patients were without functionally active adrenocortical tissue even
when their cancer failed torespond, afinding which hasrecently been confirmed by
more sensitive hormone assays (Sim et al., unpublished).
Unlike adrenalectomy and oophorectomy, implantation of the pituitary with
Yttrium-90 did not reduce total 17-ketosteroid excretion either in responding or
non-responding patients. Atrophy of the adrenals after pituitary implantation is
a gradual process andpersistent adrenal steroidgenesis may account for the higher
ketosteroid excretion compared with adrenalectomized patients (Forrest, Sim
and Stewart, 1960).
Fractionation of the urinary neutral 17-ketosteroids provides a more sensitive
and reliable estimate of adrenocortical function. Our results indicate that the
pre-operative levels of these fractions are not of value in forecasting the response
to endocrine surgery, a finding in agreement with that of Plantin et al., (1958).
Moreover, they do not confirm the recent suggestion by Allen, Hayward and
Merivale (I957, 1958), that the ratio of I I-deoxy to I I-oxy 17-ketosteroids in the
urine ofpatients with breast cancer is useful in this respect, although it must be
stressed that these workers used methods of estimation different from ours and
those of the Stockholm group.
Afteradrenalectomy and oophorectomy I I-oxy 17-ketosteroids are still present
in the urine provided maintenance cortisone is taken, and they are of value in
indicatingpersistent adrenocortical functiononly if maintenance cortisone is with-
drawn (Hobkirk etal., 1959 ; Sim etal.,unpublished). Afterpituitaryimplantation
also, cortisone isrequired to maintaingood health and metabolites wiu be excreted
as I I-oxygenated steroids. It is therefore not surprising that the levels of II
oxy 17-ketosteroids found in the urine after adrenalectomy and oophorectomy
and after destruction of the pituitary bear no relationship to the clinical response.
The 11-deoxy 17-ketosteroids are mainly metabolites of the C19 androgenic
steroids and their excretion is unlikely to be influenced by cortisone therapy
(Holliday, Kellie and Wade, 1960). Their presence in the urine of women with
breast cancer is thushighlysuggestive ofthe presence offunctioningadrenocortical,
or in the case of aetiocholanolone, possibly ovarian tissue (Plantin et al., 1958).]URINARY 17-KETOSTEROIDS IN BREAST CANCER 469
These steroids were completely absent from the urine ofnine ofsixteenpatients
after adrenalectomy and oophorectomy. In six of the remaining seven patients
small amounts of aetiocholanolone (0-01-0-04 mg./24 hr.) only were detected and
in only one patient whose cancer did not improve following adrenalectomy, were
both aetiocholanolone (0-16 mg./24 hr.) and androsterone (0-15 mg./24 hr.) found.
This latter patient did not have any clinical response to subsequent pituitarv
implantation with Yttrium-90 (100 per cent destruction) and no adrenal rests
were found post mortem.
Other workers have also described small amounts of aetiocholanolone in the
urine of adrenalectomized-oophorectomized patients (Kellie, 1954; Kellie and
Wade, 1957; BulbrookI Greenwood and Thomas, 1958). With the method we
used the quantitative significance of amounts of less than 100 #g. is doubtful
although they can be quantitatively detected down to a level approximating
IO Itg. ; it is quite clear that the presence of such small amounts of this steroid
in ttie urine of adrenalectomized patients does not preclude benefit from the
operation.
Implantation ofthepituitary with Yttrium-90 was less effective inreducing the
excretion ofthese fractions and aetiocholanolone (0-02-1-72 mg./24 hr.) was found
in the urine of twelve and androsterone (0-02-0-68 mg./24 hr.) and '8 fraction
(0-01-1-20 mg./24 hr) in the urine of seven of the twenty-two patients studied.
The amounts ofthese steroids in the urine were not related to the clinical response.
Aetiocholanolone and androsterone have also been recovered from the urine of
women with breast cancer after surgical hypophysectomy (Holliday, Kellie and
Wade, 1958)although these workers could not isolatedehydroepiandrosterone from
the urine of any of the twelve patients studied.
In our experience 11-deoxy 17-ketosteroids may still be recovered from the
urine when the intrasellar pituitary is completely destroyed, although the levels
are generally low provided 90 to 100 per cent of the gland is necrosed (Forrest
et al., 1960). It is known that aldosterone secretion persists despite complete
hypophysectomy (McLean et al., 1957) and evidence has also been presented that
cortisol synthesis also may continue in the absence of a functioning pituitarv
gland (Forrest et al., 1960). It does not seem unreasonable to suppose that the
autonomous adrenal may also be able to synthesize C19 steroids, albeit in reduced
amount, and further evidence of this has recently been reported by Wilson,
Lipsett and Butler, (1960).
The presence of 11-deoxy 17-ketosteroids in the urine of women whose breast
cancer h-ud regressed following pituitary implantation clearly indicates that pitui-
tary destruction can produce a beneficial response in the absence of full adrenal
suppression. This would suggest that deprivation of a pituitary hormone other
than corticotrophin was primarily responsible for its effect on tumour growth.
SUMMARY
Urinary 17-ketosteroids and their fractions have been estimated in women with
breast cancer before and afteradrenalectomy and oophorectomy and implantation of the pituitary gland with Yttrium-90. No relationship has been found between
pre-operative levels and the response to endocrine surgery. Following adrenalee-
omy and oophorectomy 17-ketosteroids with an 11-oxygen function, which are
derived from maintenance cortisone, persist in the urine whereas thos-- without470 SIEM, HOBKIERK, STEWART, BLAIER AN-D FORREST
this fimetion are generafly absent. Trace amounts of aetiocholanolone mav
stiH be found in the urine of somepatients afteradrenalectomy andoophorectomy
but this is not ofsignificance in relation to their response to the operation.
FoRowing pituitary implantation with Yttrium-90 both I I-oxy and II-deoxy
17-ketosteroids are more condwtently found in the urine indicating that fuLU
adrenal suppression is not required for benefit from this operation.
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